1: Goto A, Izumi-Nakaseko H, Hagiwara-Nagasawa M, Chiba K, Ando K, Naito AT, Sugiyama A. Analysis of torsadogenic and pharmacokinetic profile of E-4031 in dogs bridging the gap of information between in vitro proarrhythmia assay and clinical observation in human subjects. J Pharmacol Sci. 2018 Jun;137(2):237-240. doi: 10.1016/j.jphs.2018.06.005. Epub 2018 Jun 18. PMID: 29980434.
2: E 4031. Drugs R D. 1999 Apr;1(4):312-6. doi: 10.2165/00126839-199901040-00006. PMID: 10566051.
3: Luo C, Wang K, Zhang H. Modelling the effects of quinidine, disopyramide, and E-4031 on short QT syndrome variant 3 in the human ventricles. Physiol Meas. 2017 Sep 21;38(10):1859-1873. doi: 10.1088/1361-6579/aa8695. PMID: 28812984.
4: Izumi D, Chinushi M, Iijima K, Ahara S, Komura S, Furushima H, Hosaka Y, Sanada A, Yagihara N, Aizawa Y. Effects of bepridil versus E-4031 on transmural ventricular repolarization and inducibility of ventricular tachyarrhythmias in the dog. Pacing Clin Electrophysiol. 2010 Aug;33(8):950-9. doi: 10.1111/j.1540-8159.2010.02768.x. Epub 2010 May 4. PMID: 20487341.
5: Kim I, Boyle KM, Carroll JL. Postnatal development of E-4031-sensitive potassium current in rat carotid chemoreceptor cells. J Appl Physiol (1985). 2005 Apr;98(4):1469-77. doi: 10.1152/japplphysiol.01254.2003. Epub 2004 Dec 10. PMID: 15591286.
6: Ishii K, Nagai M, Takahashi M, Endoh M. Dissociation of E-4031 from the HERG channel caused by mutations of an amino acid results in greater block at high stimulation frequency. Cardiovasc Res. 2003 Mar;57(3):651-9. doi: 10.1016/s0008-6363(02)00774-5. PMID: 12618227.
7: Ziupa D, Beck J, Franke G, Perez Feliz S, Hartmann M, Koren G, Zehender M, Bode C, Brunner M, Odening KE. Pronounced effects of HERG-blockers E-4031 and erythromycin on APD, spatial APD dispersion and triangulation in transgenic long-QT type 1 rabbits. PLoS One. 2014 Sep 22;9(9):e107210. doi: 10.1371/journal.pone.0107210. PMID: 25244401; PMCID: PMC4170956.
8: Nikmaram MR, Liu J, Abdelrahman M, Dobrzynski H, Boyett MR, Lei M. Characterization of the effects of ryanodine, TTX, E-4031 and 4-AP on the sinoatrial and atrioventricular nodes. Prog Biophys Mol Biol. 2008 Jan- Apr;96(1-3):452-64. doi: 10.1016/j.pbiomolbio.2007.07.003. Epub 2007 Aug 1. PMID: 17850852.
9: Luo C, Wang K, Zhang H. In silico assessment of the effects of quinidine, disopyramide and E-4031 on short QT syndrome variant 1 in the human ventricles. PLoS One. 2017 Jun 20;12(6):e0179515. doi: 10.1371/journal.pone.0179515. PMID: 28632743; PMCID: PMC5478111.
10: Bai XJ, Hao JT. [Effects of E 4031 on isolated cardiac function and resting Ca2+ level of myocardial cells from rats with chronic heart failure]. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2014 Jul;30(4):364-7. Chinese. PMID: 25330678.
11: Katoh H, Ogawa S, Furuno I, Sato Y, Yoh S, Saeki K, Nakamura Y. Electrophysiologic effects of E-4031, a class III antiarrhythmic agent, on re- entrant ventricular arrhythmias in a canine 7-day-old myocardial infarction model. J Pharmacol Exp Ther. 1990 Jun;253(3):1077-82. PMID: 2359016.
12: Nagashima Y, Furukawa Y, Hirose M, Hoyano Y, Lakhe M, Chiba S. Inhibition by E-4031 of the prolongation of the first returning cycle length after overdrive in anesthetized dog hearts. J Cardiovasc Pharmacol. 1998 Jan;31(1):18-24. doi: 10.1097/00005344-199801000-00003. PMID: 9456272.
13: Michael G, Dempster J, Kane KA, Coker SJ. Potentiation of E-4031-induced torsade de pointes by HMR1556 or ATX-II is not predicted by action potential short-term variability or triangulation. Br J Pharmacol. 2007 Dec;152(8):1215-27. doi: 10.1038/sj.bjp.0707513. Epub 2007 Oct 29. PMID: 17965747; PMCID: PMC2189990.
14: Yamazaki K, Furukawa Y, Kasama M, Imamura H, Chiba S. Negative chronotropic and dromotropic effects of E-4031, an IKr blocker, on the atrioventricular node in anesthetized dog hearts. Eur J Pharmacol. 1996 Feb 22;297(3):233-9. doi: 10.1016/0014-2999(95)00753-9. PMID: 8666055.
15: Cheng J, Kamiya K, Kodama I, Toyama J. Differential effects of MS-551 and E-4031 on action potentials and the delayed rectifier K+ current in rabbit ventricular myocytes. Cardiovasc Res. 1996 Jun;31(6):963-74. PMID: 8759253.
16: Ogawa S, Mitamura H, Katoh H. Effect of E-4031, a new class III antiarrhythmic drug, on reentrant ventricular arrhythmias: comparison with conventional class I drugs. Cardiovasc Drugs Ther. 1993 Aug;7 Suppl 3:621-6. doi: 10.1007/BF00877629. PMID: 8251432.
17: Weinsberg F, Bauer CK, Schwarz JR. The class III antiarrhythmic agent E-4031 selectively blocks the inactivating inward-rectifying potassium current in rat anterior pituitary tumor cells (GH3/B6 cells). Pflugers Arch. 1997 May;434(1):1-10. doi: 10.1007/s004240050356. PMID: 9094250.
18: Goldfracht I, Efraim Y, Shinnawi R, Kovalev E, Huber I, Gepstein A, Arbel G, Shaheen N, Tiburcy M, Zimmermann WH, Machluf M, Gepstein L. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications. Acta Biomater. 2019 Jul 1;92:145-159. doi: 10.1016/j.actbio.2019.05.016. Epub 2019 May 7. PMID: 31075518.
19: Bril A, Landais L, Gout B. Actions and interactions of E-4031 and tedisamil on reperfusion-induced arrhythmias and QT interval in rat in vivo. Cardiovasc Drugs Ther. 1993 Apr;7(2):233-40. doi: 10.1007/BF00878513. PMID: 8357777.
20: Izumi-Nakaseko H, Nakamura Y, Cao X, Ohara H, Yamazaki Y, Ueda N, Ando K, Sugiyama A. Effects of selective IKr channel blockade by E-4031 on ventricular electro-mechanical relationship in the halothane-anesthetized dogs. Eur J Pharmacol. 2014 Oct 5;740:263-70. doi: 10.1016/j.ejphar.2014.06.064. Epub 2014 Jul 17. PMID: 25038475.